MedTrace Logo

Comparison of Anti-Xa Activity of ENOXA ® Versus LOVENOX ® in Acute Coronary Syndrome

NCT01687491 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 179

Last updated 2015-11-03

No results posted yet for this study

Summary

This study is a clinical trial monocentric, open, randomized ENOXA ® versus LOVENOX ®, conducted on two parallel groups of patients admitted in emergency for acute coronary syndrome.

Conditions

  • Acute Coronary Syndrome
  • Factor X

Interventions

DRUG

ENOXA®

enoxaparine 100 UI/Kg subcutaneous injection

DRUG

LOVENOX®

enoxaparine 100 UI/Kg subcutaneous injection

Sponsors & Collaborators

  • University Hospital Fattouma Bourguiba

    collaborator OTHER

  • Les Laboratoires des Médicaments Stériles

    lead INDUSTRY

Principal Investigators

  • Semir Nouira, PHD · Fattouma Bourguiba Hospital, Monastir

  • Mohsen Hassine · Fattouma Bourguiba, Monastir

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2013-05-31
Completion
2014-10-31

Countries

  • Tunisia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01687491 on ClinicalTrials.gov